Canada Markets closed

Agile Therapeutics, Inc. (AGRX)

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
Add to watchlist
0.5849-0.0151 (-2.52%)
At close: 04:00PM EST
0.5998 +0.01 (+2.55%)
After hours: 07:44PM EST
Full screen
Trade prices are not sourced from all markets
Previous Close0.6000
Open0.6105
Bid0.5800 x 1100
Ask0.5998 x 2900
Day's Range0.5651 - 0.6150
52 Week Range0.5400 - 3.7700
Volume1,663,028
Avg. Volume2,021,426
Market Cap51.625M
Beta (5Y Monthly)1.02
PE Ratio (TTM)N/A
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
  • Zacks

    Agile Therapeutics (AGRX) Reports Q3 Loss, Lags Revenue Estimates

    Agile Therapeutics (AGRX) delivered earnings and revenue surprises of 5.26% and -13.62%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?

  • Motley Fool

    Agile Therapeutics (AGRX) Q2 2021 Earnings Call Transcript

    Before we start, let me remind you that today's call will include forward-looking statements based on current expectations, including statements concerning our financial outlook for the future, management's expectations for our future financial and operational performance, our business strategy, our assessment of the combined hormonal contraceptive market and the potential market share for Twirla, among other statements regarding our plans, prospects, and expectations. Such statements represent our judgments as of today, are not promises or guarantees, and may involve risks and uncertainties that may cause actual results to differ from the results discussed in the forward-looking statements.

  • Zacks

    Agile Therapeutics (AGRX) Reports Q2 Loss, Lags Revenue Estimates

    Agile Therapeutics (AGRX) delivered earnings and revenue surprises of 4.76% and -18.28%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?